From: Lymphadenectomy in ovarian cancers: a meta-analysis of hazard ratios from randomized clinical trials
Parameters | Harter (2019) | Panici 2005 | Maggioni 2006 | |||
---|---|---|---|---|---|---|
Case N=323 n (%) | Control N=324 n (%) | Case N=216 n (%) | Control N=211 n (%) | Case N=138 n (%) | Control N=130 n (%) | |
Age (years) SD | 60 21–83 | 60 23–78 | 53 45–61 | 56 47–62 | 51 43–60 | 52 44–59 |
Median CA 125 | 416 | 347 | - | - | - | - |
FIGO stage | ||||||
1–2A | 15 | 17 | - | - | 135 | 129 |
2B–3A | 41 | 52 | - | - | - | - |
3B–4 | 261 | 244 | 216 | 211 | - | - |
Missing data | 6 | 11 | - | - | 3 | 1 |
Residual tumor | ||||||
None | 321 (99.4) | 322 (99.4) | 80 (37) | 79 (37.40) | 133 ( 96.4) | 126 (96.9) |
<1cm | N M | NM | 130 (60.2) | 118 (55.9) | 5 (3.6) | 4 (3.1) |
>1 cm | NM | NM | 4 (1.9) | 12 (5.7) | - | - |
Missing data | NM | NM | 2 (0.9) | 2 (0.9) | - | - |
Median number of resected nodes (number) | ||||||
Pelvic | 22 | - | 28.5 | 1 | 24 | 3.5 |
Paraaortic | 35 | - | 23 | 1 | 21 | 1 |
Both | 57 | - | 51.5 | 4 | 47 | 5.5 |
Tumor grade | ||||||
1 | - | - | 19 (8.8) | 11 (5.2) | 30 (21.7) | 20 (15.4) |
2 | - | - | 50 ( 23.1) | 37 (17.5) | 29 (21) | 41 (31.5) |
3 | - | - | 142 (65.7) | 160 (75.8) | 72 (52.2) | 65 (50) |
Missing data | - | - | 5 (2.3) | 3 (1.4) | 7 (5.1) | 4 (3.1) |
Cell type | ||||||
Serous | 246 (73.1) | 248 (76.6) | 132 (62.6) | 155 (71.8) | 61 (44.2) | 43 (33.1) |
Endometriod | 16 (4.9) | 18 (4.5) | 28 (13.3) | 21 (9.6) | 24 (17.4) | 34 (26.2) |
Mucinous | 3 (0.9) | 6 (1.9) | 6 (2.8) | 4 (1.9) | 14 (10.1) | 22 (16.9) |
Clear cell | 7 (2.2) | 7 (2.2) | 12 (5.7) | 4 (1.9) | 16 (11.6) | 19 (14.6) |
Undifferentiated | 34 (10.5) | 28 (8.6) | 23 (10.9) | 18 (8.3) | 7 (5.1) | 8 (6.1) |
Other | 15 (4.6) | 14 (4.3) | 8 (3.8) | 12 (5.6) | 8 (5.8) | 2 (1.5) |
Borderline tumor | 2 (0.6) | 3 (0.9) | - | - | - | - |
Missing data | - | - | 2 (0.9) | 2 (0.9) | 8 (5.8) | 2 (1.5) |
Jadad score (R+B+W) | (1+1) + (0) + (1) | (1+1) + (0) + (1) | (1+1) + (0) + (1) |